NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Hits New 52-Week High – Here’s What Happened

Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) reached a new 52-week high during trading on Saturday . The company traded as high as $6.47 and last traded at $5.30, with a volume of 30793967 shares traded. The stock had previously closed at $2.95.

NovaBay Pharmaceuticals Stock Up 79.7%

The stock’s 50 day moving average is $1.46 and its two-hundred day moving average is $1.25.

NovaBay Pharmaceuticals Dividend Announcement

The company also recently declared a dividend, which was paid on Monday, September 29th. Investors of record on Wednesday, October 1st were given a dividend of $0.80 per share. This represents a dividend yield of 3,791.0%. The ex-dividend date was Tuesday, September 30th.

Institutional Trading of NovaBay Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. C2C Wealth Management LLC grew its stake in shares of NovaBay Pharmaceuticals by 78.2% in the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 43,000 shares in the last quarter. Apollon Wealth Management LLC purchased a new position in NovaBay Pharmaceuticals during the 3rd quarter valued at about $35,000. Finally, Ground Swell Capital LLC purchased a new position in NovaBay Pharmaceuticals during the 3rd quarter valued at about $25,000. Institutional investors and hedge funds own 23.25% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.